Citigroup’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Citigroup’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43	Closed	-$508	–	5951
2022 Q4	$508	Sell	43 -230	-84%	-$4.06K	﹤0.01%	5509
2022 Q3	$6K	Sell	273 -346	-56%	-$9.33K	﹤0.01%	5185
2022 Q2	$15K	Sell	619 -5,260	-89%	-$179K	﹤0.01%	5170
2022 Q1	$293K	Sell	5,879 -15,848	-73%	-$783K	﹤0.01%	3856
2021 Q4	$1.52M	Buy	21,727 +11,213	+107%	+$945K	﹤0.01%	2847
2021 Q3	$981K	Sell	10,514 -19,095	-64%	-$1.81M	﹤0.01%	3094
2021 Q2	$2.98M	Sell	29,609 -12,582	-30%	-$1.23M	﹤0.01%	2354
2021 Q1	$3.94M	Buy	42,191 +40,637	+2,615%	+$4.12M	﹤0.01%	1967
2020 Q4	$129K	Buy	1,554 +1,004	+183%	+$85.6K	﹤0.01%	5336
2020 Q3	$47K	Sell	550 -329	-37%	-$38.3K	﹤0.01%	5651
2020 Q2	$82K	Sell	879 -860	-49%	-$47.4K	﹤0.01%	5745
2020 Q1	$50K	Buy	1,739 +457	+36%	+$17.8K	﹤0.01%	5984
2019 Q4	$53K	Buy	1,282 +894	+230%	+$19.6K	﹤0.01%	6262
2019 Q3	$6K	Sell	388 -645	-62%	-$13.5K	﹤0.01%	7295
2019 Q2	$36K	Buy	1,033 +774	+299%	+$42K	﹤0.01%	6744
2019 Q1	$15K	Hold	259	–	–	﹤0.01%	7102
2018 Q4	$12K	Sell	259 -2	-0.8%	-$110	﹤0.01%	7098
2018 Q3	$19K	Sell	261 -8	-3%	-$528	﹤0.01%	7118
2018 Q2	$22K	Sell	269 -144	-35%	-$13.9K	﹤0.01%	6874
2018 Q1	$44K	Buy	413 +115	+39%	+$13.7K	﹤0.01%	6263
2017 Q4	$39K	Buy	298 +294	+7,350%	+$36.1K	﹤0.01%	6345
2017 Q3	$0	Sell	4 -1	-20%	-$120	﹤0.01%	7489
2017 Q2	$1K	Buy	+5	New	+$675	﹤0.01%	7225

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citigroup's VBIV Position: Q1 2023 in Review

Citigroup sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 43 shares — an estimated $508 sold.

Citigroup first reported a position in VBIV in Q2 2017 and held it in 23 quarters. The position peaked at $3.94M in Q1 2021. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

Citigroup reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
Citigroup sold 43 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $508.
Citigroup first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 23 quarters.
Citigroup's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $3.94M in Q1 2021.
95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.